← Dashboard
Stock
CVS
CVS HEALTH CorpHealth CareHealth Care ServicesLatest close $968 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
8
27 funds tracked
Ever held
14
Current + past
New this quarter
2
Exited this quarter
2
Marquee-fund ownership over time
Nov 13, 2013Aug 14, 2018Nov 14, 2023May 15, 2026
Now
8
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q4 2013 | 51Q | $46 | $96 | +110% |
| Glenview Capital re-entered | Q4 2017 | 35Q | $54 | $96 | +79% |
| Maverick Capital re-entered | Q3 2020 | 24Q | $54 | $96 | +76% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $52 | $96 | +84% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $52 | $96 | +84% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $52 | $96 | +84% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $52 | $96 | +84% |
| Renaissance Technologies re-entered | Q4 2024(8Q snapshot) | 6Q | $51 | $96 | +88% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q3 2024 | Q2 2026 | → $96 | +84% |
| Point72 Asset Management 2× in & out | Q4 2025 | Q2 2026 | → $96 | +25% |
| Third Point | Q4 2024 | Q1 2025 | → $63 | +21% |
| Scion Asset Management 4× in & out | Q1 2024 | Q2 2024 | → $52 | -26% |
| Coatue Management 3× in & out | Q3 2020 | Q4 2020 | → $61 | +13% |
| Viking Global Investors | Q2 2018 | Q3 2018 | → $56 | +9% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at CVS HEALTH Corp. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
17
Filings · last 90d
27
Total on file
537
Recent SEC buffer
Most recent
Jun 1, 2026
30d / 90d windows measured from Jun 1, 2026 — the most recent Form 4 on file — not from today.
- Form 40000064803-26-000088Jun 1, 2026
- Form 40000064803-26-000086Jun 1, 2026
- Form 40000064803-26-000084May 22, 2026
- Form 40000905148-26-002617May 21, 2026
- Form 40000064803-26-000080May 15, 2026
- Form 40000064803-26-000078May 15, 2026
- Form 40000064803-26-000076May 15, 2026
- Form 40000064803-26-000074May 15, 2026
- Form 40000064803-26-000072May 15, 2026
- Form 40000064803-26-000070May 15, 2026
- Form 40000064803-26-000068May 15, 2026
- Form 40000064803-26-000066May 15, 2026
- Form 40000064803-26-000064May 15, 2026
- Form 40000064803-26-000062May 15, 2026
- Form 40000064803-26-000060May 15, 2026
Showing 15 of 537 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · CVS HEALTH CorpAnnual figures sourced directly from CVS HEALTH Corp's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$402.07B
FY2025+8% YoY
Net income
$1.77B
FY2025-62% YoY
EPS (diluted)
$1.39
FY2025-62% YoY
Free cash flow(?)
$7.81B
FY2025+23% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for CVS HEALTH Corp — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 18, 2026
- 10-QQuarterly reportMay 6, 2026
- 8-KMaterial eventMay 6, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTApr 3, 2026
- 8-KMaterial eventMar 19, 2026
- 10-KAnnual reportFeb 10, 2026
- 8-KMaterial eventFeb 10, 2026
- 8-KMaterial eventDec 9, 2025
- 8-KMaterial eventNov 20, 2025
- 10-QQuarterly reportOct 29, 2025
- 8-KMaterial eventOct 29, 2025
- 8-KMaterial eventSep 22, 2025
- 8-KMaterial eventAug 15, 2025
- 10-QQuarterly reportJul 31, 2025
- 8-KMaterial eventJul 31, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Maverick Capital | Q2 2026 | open | $96 | $90 | -6% |
| Renaissance Technologies | Q2 2026 | open | $97 | $96 | -1% |
| Point72 Asset Management | Q4 2025 | Q2 2026 | $77 | $96 | +25% |
| Renaissance Technologies | Q2 2025 | Q1 2026 | $58 | $77 | +33% |
| Third Point | Q4 2024 | Q1 2025 | $52 | $63 | +21% |
| Point72 Asset Management | Q4 2024 | Q2 2025 | $52 | $58 | +12% |
| Renaissance Technologies | Q4 2024 | Q1 2025 | $51 | $63 | +24% |
| Citadel Advisors | Q3 2024 | open | $52 | $96 | +84% |
| Two Sigma Investments | Q3 2024 | Q2 2026 | $52 | $96 | +84% |
| D.E. Shaw | Q3 2024 | open | $52 | $96 | +84% |
| AQR Capital Management | Q3 2024 | open | $52 | $96 | +84% |
| Millennium Management | Q3 2024 | open | $52 | $96 | +84% |
| Glenview Capital | Q1 2024 | open | $70 | $96 | +38% |
| Scion Asset Management | Q1 2024 | Q2 2024 | $70 | $52 | -26% |
| Scion Asset Management | Q3 2023 | Q4 2023 | $67 | $62 | -7% |
| Maverick Capital | Q1 2023 | Q1 2024 | $78 | $70 | -11% |
| Scion Asset Management | Q2 2021 | Q1 2022 | $72 | $89 | +24% |
| Maverick Capital | Q2 2021 | Q3 2021 | $72 | $73 | +2% |
| Scion Asset Management | Q4 2020 | Q1 2021 | $61 | $59 | -3% |
| Coatue Management | Q3 2020 | Q4 2020 | $54 | $61 | +13% |
| Maverick Capital | Q3 2020 | Q1 2021 | $54 | $59 | +9% |
| Bridgewater Associates | Q2 2020 | open | $51 | $90 | +76% |
| Coatue Management | Q4 2018 | Q1 2020 | $63 | $58 | -7% |
| Viking Global Investors | Q2 2018 | Q3 2018 | $51 | $56 | +9% |
| Coatue Management | Q2 2018 | Q3 2018 | $52 | $56 | +8% |
| Bridgewater Associates | Q1 2018 | Q1 2020 | $54 | $59 | +9% |
| Glenview Capital | Q4 2017 | Q2 2019 | $54 | $42 | -22% |
| Bridgewater Associates | Q1 2017 | Q3 2017 | $59 | $60 | +2% |
| Bridgewater Associates | Q3 2016 | Q4 2016 | $72 | $57 | -21% |
| Bridgewater Associates | Q1 2016 | Q2 2016 | $69 | $76 | +11% |
| Bridgewater Associates | Q1 2015 | Q2 2015 | $74 | $74 | -0% |
| Bridgewater Associates | Q4 2013 | Q1 2014 | $46 | $49 | +7% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.